Location of Repository

Serum resistin is associated with C-reactive protein and LDL- cholesterol in type 2 diabetes and coronary artery disease in a Saudi population

By Nasser M. Al-Daghri, R. Chetty, P. G. (Philip G.) McTernan, K. Al-Rubean, Omar S. Al-Attas, A. F. Jones and Sudhesh Kumar

Abstract

Aims\ud Resistin is an adipocyte-derived factor implicated in obesity-associated type 2 diabetes (T2DM). This study examines the association between human serum resistin, T2DM and coronary heart disease.\ud \ud Methods\ud One hundred and fourteen Saudi Arabian patients (male: female ratio 46:68; age 51.4 (mean ± SD)11.7 years; median and range: 45.59 (11.7) years and BMI: 27.1 (mean ± SD) 8.1 Kgm2 median and range: 30.3 (6.3) were studied. Serum resistin and C-reactive protein (CRP), a marker of inflammation CRP levels, were measured in all subjects. (35 patients had type 2 diabetes mellitus (T2DM); 22 patients had coronary heart disease (CHD).\ud \ud Results\ud Serum resistin levels were 1.2-fold higher in type 2 diabetes and 1.3-fold higher in CHD than in controls (p = 0.01). In addition, CRP was significantly increased in both T2DM and CHD patients (p = 0.007 and p = 0.002 respectively). The use of regression analysis also determined that serum resistin correlated with CRP levels (p = 0.04, R2 0.045).\ud \ud Conclusion\ud The findings from this study further implicate resistin as a circulating protein associated with T2DM and CHD. In addition this study also demonstrates an association between resistin and CRP, a marker of inflammation in type 2 diabetic patients.\ud \u

Topics: RC
Publisher: BioMed Central Ltd.
Year: 2005
OAI identifier: oai:wrap.warwick.ac.uk:578

Suggested articles

Preview

Citations

  1. (2002). AM: Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res doi
  2. (2004). Assessing coronary heart disease risk with traditional and novel risk factors. Clin Cardiol doi
  3. (2004). Boyko EJ: Type 2 diabetes prevalence in Asian Americans: results of a national health survey. Diabetes Care doi
  4. (2003). CJ: Anti-TNF-alpha antibody normalizes serum leptin in IL-2 deficient mice. doi
  5. (2004). Colonic leptin: source of a novel proinflammatory cytokine involved in IBD.
  6. (2003). Considine RV: Serum resistin (FIZZ3) protein is increased in obese humans. doi
  7. (1995). Diabetes and related metabolic risk factors among Arab Americans. Ann Pharmacother
  8. (2004). Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta doi
  9. (2000). FIZZI, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines new gene family. Embo J doi
  10. (2001). Fruhbeck G: Do resistin and resistin-linke molecules also link obesity to inflammatory diseases? Ann Intern Med doi
  11. (2002). HS: Pref-1 and ADSF/resistin: two secreted factors inhibiting adipose tissue development. Horm Metab Res doi
  12. (2004). Inflammation : the lind between insulin resistance, obesity and diabetes. Trends Immunol doi
  13. (2004). Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care doi
  14. (2003). Inflammatory pathways and insulin action. doi
  15. (2004). JP: Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL6 levels in obese women. Int J Obes Relat Metab Disord . doi
  16. (1995). JS: Pattern of non-insulin dependent diabetes mellitus in Kuwait. Diabetes Res Clin Pract doi
  17. (1993). Koretzky GA: CD45 and the immune response.
  18. (2003). LJ: Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlation with insulin resistance. doi
  19. (2004). MA: Abnormal Glucose Homeostasis due to Chronic Hyperresistinemia. Diabetes in press. doi
  20. (2003). Mantzoros CS: Circulating resistin levels are not associated with obesity or insulin resistance in humans and not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. doi
  21. (2004). Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism doi
  22. (2004). Relationship between serum resistin concentration and insulin resistance in nonobese, obese, and obese diabetic subjects. doi
  23. (2003). Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. doi
  24. (2003). Resistin is expressed in human macrophages and directly regulated by PPARagnna activators. Biochem Biophys Res Commun doi
  25. (2002). Resistin, central obesity, and type 2 diabetes. Lancet doi
  26. (1985). RL: Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia doi
  27. (1999). Roaded RB: Epidemiological and clinical patterns of diabetes mellitus in Benghazi, Libyan Arab Jamahiriya. East Mediterr Health J
  28. (2004). S: Significant increase in maternal plasma leptin concentration in induce delivery: a possible contribution of pro-inflammatory cytokines to placental leptin secretion. Endocr J doi
  29. (2003). Saruta T: Correlation between serum resistin level and adiposity in obese individuals. Obes Res doi
  30. (2003). Scherer PE: Minireview: The adipocyte at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology doi
  31. (2004). Tatarnni PA: High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indian. Diabetes doi
  32. (2001). The hormone resistin links obesity to diabetes. Nature
  33. (1985). The South all Diabetes Survey: prevalence of known diabetes in Asians and Europeans. Br Med J doi
  34. (2004). Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian-Indian epidemic. Curr Diab Rep doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.